A meningioma is one of the most common findings on a brain MRI, and one of the least dangerous. Most are small, slow, benign, and picked up entirely by accident when someone was scanned for a migraine, dizziness or a head injury. What tends to unsettle people is not the tumour itself but the plan around it - the calendar of follow-up scans that begins the moment the letter arrives. This is what that calendar looks like in the UK in 2026, and what actually changes at each step.
None of what follows is a substitute for the neurosurgery or neuro-oncology team looking after you. But it is what a well-informed patient can reasonably expect, so the surveillance feels less like a mystery and more like a routine.
One-line answer
Most meningiomas in the UK are watched, not treated: baseline MRI, then follow-up scans at six months, twelve months and twenty-four months, then extending intervals if the tumour is stable, with treatment reserved for growth, symptoms or atypical features.
What a meningioma actually is
A meningioma is a tumour that grows from the meninges - the thin protective layers that wrap the brain and spinal cord - and specifically from a cell type called an arachnoid cap cell. It is not a brain tumour in the sense of arising from brain tissue. It sits outside the brain and pushes on it, which matters for both symptoms and surgical planning.
The overwhelming majority - roughly 80 to 85 per cent - are WHO grade 1, meaning benign and slow-growing. A smaller number are grade 2 (atypical) or grade 3 (anaplastic, malignant), which behave more aggressively and are managed differently. Grade is not something you can read off a scan alone. It is usually confirmed only after surgery, on the histology. But imaging features can suggest which grade is likely, and that shapes the plan.
The incidental meningioma pattern
The single most common way a meningioma is diagnosed in the UK in 2026 is entirely by accident. Someone has an MRI for chronic headache, tinnitus, dizziness, a head injury, or as part of a work-up for something completely unrelated, and the radiologist notes a small enhancing extra-axial lesion consistent with a meningioma.
These incidental meningiomas share a pattern: small (often under 2 cm), asymptomatic, in a location that is not causing pressure on anything critical, and stable on any prior imaging that happens to be available. For this group, the answer is almost never surgery. It is surveillance.
Being told you have a brain tumour, even a benign one, is a disorienting sentence to read. It is worth saying plainly: an incidental grade 1 meningioma in an adult of average life expectancy has, in most cases, a very low probability of ever needing treatment. The follow-up MRI schedule exists precisely to confirm that quiet trajectory - not to catch a disaster in the making.
The standard surveillance schedule
UK practice has converged, broadly, on a pattern that looks like this. It comes from the EANO (European Association of Neuro-Oncology) guidelines, the British Neuro-Oncology Society position, and how most UK neurosurgical units run their meningioma clinics day-to-day.
| Scan | When | What it does |
|---|---|---|
| Baseline MRI | At diagnosis | Establishes size, location, imaging features, and reference measurements for every future comparison. |
| First follow-up | 6 months | Detects unusually rapid early growth. Rare, but the reason this scan exists. |
| Second follow-up | 12 months from baseline | Confirms the growth trajectory over a full year. |
| Third follow-up | 24 months from baseline | If stable, the plan usually shifts to less frequent intervals. |
| Extended surveillance | Every 2 to 3 years | Continues if the tumour remains stable and asymptomatic. |
| Long-term or discharge | 5-yearly or ended | For small, stable, calcified lesions, particularly in older patients. |
This is a pattern, not a prescription. Neurosurgeons individualise it. A meningioma in an awkward location, near the optic nerve or a venous sinus, may be watched more closely. A tiny calcified lesion in an 80-year-old may be discharged after two stable scans. The schedule bends around the tumour and the patient.
What the follow-up MRI protocol includes
A meningioma follow-up is not a generic brain scan. The protocol is designed to measure the tumour precisely and pick up subtle change. A well-run UK protocol typically includes:
- T1-weighted post-gadolinium sequences. Meningiomas enhance brightly and homogeneously with contrast. This is the sequence that defines the tumour edges and lets the radiologist measure it in three planes.
- T2-weighted imaging. Shows the tumour in relation to surrounding brain, and highlights any peri-tumoural oedema (brain swelling around the lesion).
- FLAIR. Sensitive to oedema and to any new signal change in adjacent brain tissue.
- Diffusion-weighted imaging (DWI). Helps distinguish atypical or higher-grade features from benign ones.
- MR spectroscopy or perfusion imaging. Not routine. Added when the appearance is unusual or a differential (schwannoma, haemangiopericytoma, dural metastasis) needs to be excluded.
Slice thickness, coil selection and scanner field strength (typically 1.5T or 3T) all affect how sensitive the study is to millimetre-level growth. This is why continuity matters. A scan done on a different machine, with different parameters, can make a stable tumour look as if it has changed simply because the images are not directly comparable.
When the plan changes
The reason for the calendar is to catch the small minority of meningiomas that shift out of the "watch" category. A neurosurgical MDT will typically move from surveillance to active treatment when one of the following is documented:
- Measurable growth. Consistent enlargement across two consecutive scans, usually defined as a change of a few millimetres in maximum diameter or an increase in tumour volume.
- New or worsening symptoms. Headaches, seizures, visual changes, hearing loss, limb weakness, personality change - anything that can plausibly be attributed to the lesion.
- New peri-tumoural oedema. Brain swelling around the tumour is a signal that the lesion is starting to affect the surrounding tissue.
- Atypical imaging features. Heterogeneous enhancement, unusual invasion of adjacent structures, or a suggestion of higher-grade behaviour on DWI or spectroscopy.
- Location and trajectory concern. Even slow growth becomes clinically relevant if the tumour is near the optic nerves, brainstem, or a major venous sinus.
Any of these is a reason to discuss the case at a neuro-oncology MDT and consider intervention. None of them is, on its own, an emergency.
